The Novartis decision of the Indian Supreme Court rejecting patentability of the cancer drug, Imatinib Mesylate in its beta crystalline form (commonly called 'Glivac'), has been commended for its outlook on public interest and access to health. It was in fact an important decision for cancer patients as it removes the last possible hurdle to access the drug at one-tenth of its cost, which was around Rs. 1, 20, 000/- per month. The main issue in the case revolved around…
To know more about BananaIP Counsels (Earlier known as Brain League) visit bananaip.com
Biotechnology Industry Partnership Programme (BIPP) is a new partnership programme with industries for support on a cost-sharing basis for high-risk discovery and innovation, accelerated technology development especially for futuristic areas like transformational technology and product development for the public good, areas having major economic potential with focused on IP creation with ownerships by Indian industry, development of technologies in the area of agriculture, health, bio-energy, green manufacturing etc.
The objective is to assist and promote emerging biotech entrepreneurs and facilitate innovative…